Li P, Yokomori K, Tsuchida Y, Fujita M, Shimizu K, Tanaka E, Pianovski M A, Takemura T
Department of Pediatric Surgery, University of Tokyo, Japan.
Tumour Biol. 1995;16(6):385-93. doi: 10.1159/000217955.
We studied, by flow cytometry, the DNA contents of paraffin-embedded tumor specimens from 90 infants and children with kidney tumors, and analyzed the relationship of DNA ploidy with histological types and prognosis. Data of adequate quality were obtained from 90 cases: 65 tumors with favorable histology, 5 congenital mesoblastic nephromas and 20 tumors with unfavorable histology. The 90 cases had nuclear DNA histogram patterns that were classified as DNA diploid in 64 tumors, aneuploid in 19 and tetraploid in 7. There were no significant correlations between DNA ploidy and histological types or clinical stages. Survival rates for patients with diploidy were 80 and 70% at 2 and 5 years, respectively, and those of patients with aneuploidy were 72 and 61% at 2 and 5 years, respectively. On the other hand, patients with a DNA tetraploid pattern had significantly worse survival rates of 43 and 29% at 2 and 5 years, respectively. Among patients with aneuploidy or tetraploidy, the S-phase fractions in those who died (mean +/- SD: 10.3 +/- 4.1 and 22.1 +/- 11.6%, respectively) appear to be greater than those in their surviving counterparts (8.8 +/- 4.0 and 12.1 +/- 2.8%). Hence, although the differences between diploid and aneuploid DNA patterns were not correlated with differential prognosis in children with kidney tumors, a tetraploid pattern clearly indicates a poor prognosis, especially in combination with histological types and clinical stages.
我们通过流式细胞术研究了90例婴幼儿肾肿瘤石蜡包埋肿瘤标本的DNA含量,并分析了DNA倍体与组织学类型及预后的关系。从90例病例中获得了质量合格的数据:65例组织学类型良好的肿瘤、5例先天性中胚层肾瘤和20例组织学类型不良的肿瘤。90例病例的核DNA直方图模式分类如下:64例肿瘤为DNA二倍体,19例为非整倍体,7例为四倍体。DNA倍体与组织学类型或临床分期之间无显著相关性。二倍体患者2年和5年的生存率分别为80%和70%,非整倍体患者2年和5年的生存率分别为72%和61%。另一方面,DNA四倍体模式的患者2年和5年的生存率分别显著较差,为43%和29%。在非整倍体或四倍体患者中,死亡患者的S期分数(平均±标准差:分别为10.3±4.1%和22.1±11.6%)似乎高于存活患者(8.8±4.0%和12.1±2.8%)。因此,虽然二倍体和非整倍体DNA模式之间的差异与肾肿瘤患儿的预后差异无关,但四倍体模式显然表明预后不良,尤其是与组织学类型和临床分期相结合时。